Medindia LOGIN REGISTER
Medindia
Advertisement

Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor

Monday, April 22, 2019 General News
Advertisement
Novel Inflammasome inhibitor, which uniquely targets ASC, represents a differentiated approach to block abnormal immune responses driving the onset of inflammatory diseases

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close